$CERO News

Last published 1w ago

1w agoCEROCERo Therapeutics Doses 7th Patient in Phase 1 CER-1236 TrialGlobeNewswireSeventh patient of the trial at the second cohort SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative
2w agoCEROCERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic MalignanciesGlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company advancing
2w agoSRXH CEROSRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic MalignanciesGlobeNewswireUC Davis is the primary manufacturing site for CER-1236, site activation is expected to expand patient recruitment capacity and streamline treatment logistics Update follows SRX’s previously announced definitive
2w agoCEROCERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological CancersGlobeNewswireSOUTH SAN FRANCISCO, Calif, Oct. 26, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company advancing
1mo agoSRXH CEROSRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic MalignanciesGlobeNewswireSPV, CERO 1236, to raise capital directly into subsidiary and not dilute existing SRX Global shareholders Proposed acquisition expected to accelerate development of CERo's lead product candidate, CER-1236, for
2mo agoSRXH CEROSRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic CancersGlobeNewswireNORTH PALM BEACH, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE:SRXH) (the "Company" or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through
4mo agoCEROCERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following TreatmentGlobeNewswireFifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic malignancies SOUTH SAN
6mo agoCEROCERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 TrialGlobeNewswireCompany to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics
7mo agoCEROCERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 TrialGlobeNewswireStudy will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF) SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.,
7mo agoCEROCERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 TrialGlobeNewswireTrial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF SOUTH SAN FRANCISCO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB:CERO)
8mo agoCERO CRVO SCYXCERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of DirectorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel
9mo agoCEROCERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML PatientGlobeNewswirePoster to be presented at Tandem Meeting of the American Society of Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) on February 5, 2026 SOUTH
10mo agoCEROCERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AMLGlobeNewswireCompany to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.,
10mo agoCEROCERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)GlobeNewswireCompletion of DLT observation period for Cohort 1; first patient in Cohort 2 dosed at higher cell level; additional dosing in Cohort 1 SOUTH SAN FRANCISCO, Calif., Dec. 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics
11mo agoCEROCERo Therapeutics Announces Trading on OTCQB MarketGlobeNewswireCompany's Shares Will Continue to Trade Under Ticker CERO
1y agoCEROCERo Therapeutics Announces Receipt of Nasdaq Panel DeterminationGlobeNewswireTrading of the Company's shares of common stock on Nasdaq will be suspended at the open of trading on October 31 CERo plans to appeal the Panel determination, seek trading of its shares on the OTC Markets and continue
1y agoCEROCERo Therapeutics Announces Third Dose for Patient in Phase 1 Clinical Trial of CER-1236 in AMLGlobeNewswireCompany completes first tranche of a $7 million financing to increase cash runway and maintain Nasdaq compliance SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.
1y agoCEROCERo Therapeutics to Participate in Stem Cell Therapy Panel at the Maxim Growth Summit 2025GlobeNewswireSOUTH SAN FRANCISCO, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company, announces that Chris Ehrlich,
1y agoCEROCERo Therapeutics Announces Completion of First Cohort of Phase 1 Clinical Trial of CER-1236 in AMLGlobeNewswireStudy's Dose Escalation Safety Committee approves initiation of Cohort 2 with fourth patient to receive increase in initial dose pending regulatory approval Company issues correction of recently published article,
1y agoCEROCERo Therapeutics Progresses Phase 1 CER-1236 AML Trial with Dosing of Third Patient in Initial Dose CohortGlobeNewswireThird patient in the first cohort is now advancing through protocol-defined evaluations as Company anticipates additional results from second dosing of second patient in the cohort SOUTH SAN FRANCISCO, Calif, Sept. 22,
1y agoCEROCERo Therapeutics Receives Notice of Allowance from U.S. Patent and Trade Office on Composition of Matter and Method of Use for CER-1236 in Cancer with Expected Protection Through 2041GlobeNewswireAdditional patent granted from the Japanese patent office now results in 20 granted patents and allowed applications covering the compound and its underlying technology SOUTH SAN FRANSCISCO, Calif., Sept. 09, 2025
1y agoCEROCERo Therapeutics Announces Dose Intensification in Phase 1 Study of CER-1236 in Acute Myeloid LeukemiaGlobeNewswireStudy investigator of Phase 1 trial presented poster at Society of Hematologic Oncology 13th annual conference highlighting original study protocol SOUTH SAN FRANSCISCO, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) --
1y agoCEROCERo Therapeutics Receives FDA Fast Track Designation for CER-1236 in Acute Myeloid Leukemia (AML)GlobeNewswireRegulatory milestone adds to its existing Orphan Drug Designation, creating additional regulatory and financial advantages for the Company's lead cancer immunotherapy program SOUTH SAN FRANSCISCO, Calif., Sept. 05,
1y agoCEROCERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236GlobeNewswireSecond patient in the first cohort is now advancing through protocol-defined evaluations as Company provides promising update on first patient pharmacokinetic results SOUTH SAN FRANSCISCO, Calif., July 31, 2025 (GLOBE
1y agoCEROCERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML)GlobeNewswireSOUTH SAN FRANSCISCO, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of
1y agoCEROCERo Therapeutics Holdings, Inc. Announces Reverse Stock SplitGlobeNewswireSOUTH SAN FRANSCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of
1y agoCEROCERo Therapeutics, Inc. Announces Option Exercise for Additional Series D FinancingGlobeNewswireSOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell
1y agoCEROCERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236GlobeNewswireResults in 18 Issued Patents and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.,
1y agoCEROCERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined EvaluationsGlobeNewswireCERO Chief Medical Officer to discuss trial protocol in poster at the American Society for Clinical Oncology Conference The first patient has been dosed and is advancing through protocol-defined evaluations SOUTH SAN
1y agoCEROCERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)GlobeNewswireSOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of
1y agoCEROCERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid LeukemiaGlobeNewswireSOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of
1y agoCEROCERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual MeetingGlobeNewswireSOUTH SAN FRANCISCO, Calif, April 25, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of
1y agoCEROCERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid LeukemiaGlobeNewswireSOUTH SAN FRANSCISCO, Calif, April 24, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of
1y agoCEROCERo Therapeutics, Inc. Announces Up to $8 Million Series D FinancingGlobeNewswireSOUTH SAN FRANCISCO, Calif, April 22, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell
1y agoCEROCERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236GlobeNewswireResults in 17 Issued and Allowed Patent Applications Internationally with Nine Total Patent Families SOUTH SAN FRANSCISCO, Calif, April 10, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO)
1y agoCEROCERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid LeukemiaGlobeNewswireSOUTH SAN FRANSCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of
1y agoCEROCERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid TumorsGlobeNewswireSOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of
1y agoCEROCERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of ManufacturingGlobeNewswireCompany reports acceptance of an abstract at the 2025 American Society of Clinical Oncology (ASCO) conference; Continues to be on track to dose first patient in first half of 2025 SOUTH SAN FRANSCISCO, Calif., March
1y agoCEROCERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing ServicesGlobeNewswireCompany continues to improve its market position as it nears launch of its Phase 1 clinical trial in AML SOUTH SAN FRANSCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO)
1y agoCEROCERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors MeetingGlobeNewswireSOUTH SAN FRANSCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of
1y agoCEROCERo Therapeutics Holdings, Inc. Announces Progress in Initiation of Phase 1 Clinical Trial by Executing an Agreement with Contract Research Organization CellCarta to Manage Translational AssaysGlobeNewswireCompany continues toward the initiation of its Phase 1 Clinical Trial in AML for CER-1236 SOUTH SAN FRANSCISCO, Calif., March 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or
1y agoCEROCERo Therapeutics Holdings, Inc. to Present Data at the Society for Immunotherapy of Cancer Spring Scientific March 12-14GlobeNewswireNew poster to highlight preclinical data of CER-1236 in ovarian cancer SOUTH SAN FRANSCISCO, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an
1y agoCEROCERo Therapeutics Holdings, Inc. Highlights ProgressGlobeNewswireIncreased cash balance and momentum with both Nasdaq and Phase 1 trial initiation mark strong beginning for 2025 SOUTH SAN FRANSCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.,
1y agoCEROCERo Therapeutics Announces $5 Million Public Offering Priced At-The-Market Under Nasdaq RulesGlobeNewswireSOUTH SAN FRANSCISCO, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of
1y agoCEROCERo Therapeutics Holdings, Inc. Announces Reverse Stock SplitGlobeNewswireSOUTH SAN FRANSCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of
1y agoCEROCERo Therapeutics, Inc. Appoints Chris Ehrlich CEOGlobeNewswireSOUTH SAN FRANCISCO, Calif, Dec. 06, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell
1y agoCEROCERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous LeukemiaGlobeNewswireSOUTH SAN FRANCISCO, Calif, Nov. 15, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell
2y agoCEROCERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without ToxicityGlobeNewswireData presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy
2y agoCEROCERo Therapeutics, Inc. Provides Corporate UpdateGlobeNewswireCompany announces submission of IND Clinical Hold Complete Response Letter SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative
2y agoCEROCERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development OfficerGlobeNewswireSOUTH SAN FRANCISCO, Calif, Oct. 02, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (NASDAQ:CERO) ("CERo"), an innovative immunotherapy company seeking to advance the next generation of engineered T cell